Exelixis | EXEL - Cost Of Sales


Exelixis reported $19.95M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 28.32M 3.52M Jun/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Akebia Therapeutics USD 10.34M 441K Dec/2025
Amgen USD 1.87B 271M Jun/2026
AstraZeneca USD 2.52B 2.73B Jun/2026
Bayer EUR 5.23B 731M Mar/2026
BioMarin Pharmaceutical USD 276.29M 76.8M Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Cytokinetics USD 5.59M 5.43M Jun/2026
Eisai JPY 51.09B 926M Jun/2026
Eli Lilly USD 3.27B 309M Jun/2026
Exelixis USD 19.95M 6.53M Mar/2026
Genmab DKK 84M 19M Jun/2026
Glaxosmithkline GBP 1.88B 1.6B Mar/2026
Incyte USD 104.96M 457K Jun/2026
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
MacroGenics USD 9.53M 585K Mar/2026
Merck USD 3.14B 200M Jun/2026
Moderna USD 93M 862M Jun/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 39.4M 25.6M Jun/2026
Novartis USD 3.71B 251M Jun/2026
Pfizer USD 4.09B 498M Jun/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Sanofi EUR 3.14B 618M Mar/2026
Takeda JPY 517.6B 42.94B Jun/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Xencor USD 61.66M 50.95M Jun/2025